Clinical trial data support the NDA for TEV-'749, demonstrating that once-monthly olanzapine improves symptoms in patients with schizophrenia. The Food and Drug Administration (FDA) has accepted for ...
At the time of analysis, no cases of post injection delirium syndrome were reported. A once-monthly subcutaneous formulation of olanzapine (TEV-’749) was found to improve symptoms in patients with ...
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE ...
(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting ...
Federal regulators are investigating the deaths of two patients who received injections of a longer-lasting version of Eli Lilly’s antipsychotic Zyprexa. The Food and Drug Administration said Tuesday ...
MONTPELLIER, France--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22 nd Annual Global Healthcare ...
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic ...
PARSIPPANY, N.J. and TEL AVIV - Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Medincell (Euronext:MEDCL) announced today that the U.S. Food and Drug Administration has accepted their ...
SILVER SPRING, Md., Feb 6 (Reuters) - A U.S. advisory panel on Wednesday backed Eli Lilly and Co's proposed long-acting form of schizophrenia drug Zyprexa. Sign up here. Advisers to the Food and Drug ...
To fuel CEO Richard Francis’s “pivot to growth” plan, Teva has turned to royalty financing to fuel the accelerated development of a pipeline antipsychotic drug in its innovation portfolio. Teva has ...
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results